BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

...Spark Therapeutics Inc. alum Katherine High as president, therapeutics. As president and head of R&D at Spark, High...
...she was also an investigator at the Howard Hughes Medical Institute. Roche (SIX:ROG; OTCQX:RHHBY) acquired Spark...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Jan 7, 2021
Finance

Weill Cornell spinout Lexeo raises $85M series A to develop clinical gene therapy programs

...the founding former chairman of gene therapy company Spark Therapeutics Inc. Roche (SIX:ROG; OTCQX:RHHBY) acquired Spark...
BioCentury | Dec 31, 2020
Politics, Policy & Law

Innovations forged in the COVID crucible will reshape medicine

The fight against COVID-19 is far from finished, but victory is close enough to start considering how the tools created to tame SARS-CoV2 will reshape the post-war world. As with World War II and the...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...
BioCentury | Dec 18, 2020
Product Development

Sangamo’s Macrae on where the gene editing field is headed: a BioCentury audio interview

...from certain acquisitions such as Roche acquiring Spark...
BioCentury | Dec 17, 2020
Emerging Company Profile

Vigil: restoring the vigilance of microglia

Incubated by Atlas Venture and led by former Ipsen CBO Ivana Magovčević-Liebisch, Vigil launched last week with $50 million in series A financing to advance two TREM2 agonists in-licensed from Amgen in rare microgliopathy indications. “We’ve...
BioCentury | Nov 17, 2020
Management Tracks

Gujrathi leaving as Gossamer CEO; plus Spark, Atlas, Flagship, Talaris

...roles in which she will be succeeded by Chairman Faheem Hasnain.Michael Retterath joined gene therapy play Spark...
...year, Talaris raised $100 million in a series A round led by Blackstone Life Sciences. BC Staff Spark Gossamer Atlas...
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

...its second candidate into the clinic; and SPARK...
...—chicken antibodies —against the SARS-CoV-2 spike.SPARK...
...of SPARK Global, an expansion of the SPARK...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

Although VelosBio appeared to be heading down the path to an IPO, the oncology company has instead accepted a $2.8 billion takeout offer from Merck now that the biotech’s antibody-drug conjugate has shown signs of...
Items per page:
1 - 10 of 566